Mouse Anti-BCL10 Recombinant Antibody (VS3-CJ197) (CAT#: VS3-CJ197)

• Immunogen
• KLH-conjugated synthetic peptide between 1-143 amino acids from the human region of human BCL10

• Host Species
• Mouse

• Type
• Mouse IgG1, κ

• Specificity
• Human BCL10

• Species Reactivity
• Human

• Applications
• WB, IHC-P, FC

• Conjugate
• Unconjugated

• Purification
• Protein G affinity purified

• Purity
• >95% as determined by SDS-PAGE

• Buffer
• PBS

• Preservative
• 0.09% sodium azide

• Storage
• Store at 4°C for short term. Aliquot and store at -20°C for long term. Avoid repeated freeze/thaw cycles.

• Shipping
• Ice packs

• Application Notes
• This antibody has been tested for use in Western Blot (1:1000), Flow Cytometry (1:25), Immunohistochemistry-Parraffin (1:25).

• Alternative Names
• CLAP; hCLAP; CIPER; CARMEN; cCARMEN; c-E10; mE10; CIPER; IMD37

• Gene ID
• 8915

• UniProt ID
• O95999

• Cellular Localization
• Cytoplasm, Membrane

• Post Translation Modifications
• Phosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2 (PubMed:11466612).
  Phosphorylated by IKBKB/IKKB (PubMed:17213322).
  Ubiquitinated via both 'Lys-63'-linked and linear ('Met-1'-linked) polyubiquitin chains in response to T-cell receptor (TCR) activation (PubMed:18287044, PubMed:27777308).
  Ubiquitination is recognized by IKBKG/NEMO, the regulatory subunit of I-kappa-B kinase (IKK), and is required for TCR-induced NF-kappa-B activation (PubMed:18287044, PubMed:27777308).
  Linear ubiquitination at Lys-17, Lys-31 and Lys-63 is mediated by RNF31/HOIP; linear ubiquitination is recognized with much higher affinity than 'Lys-63'-linked ubiquitin by IKBKG/NEMO (PubMed:27777308).
  CARD11 is required for linear ubiquitination by HOIP by promoting the targeting of BCL10 to RNF31/HOIP (PubMed:27777308).
  Proteolytically cleaved by MALT1; required for T-cell activation.

• Protein Refseq
• NP_003912.1

• Function
• Plays a key role in both adaptive and innate immune signaling by bridging CARD domain-containing proteins to immune activation (PubMed:10187770, PubMed:10364242, PubMed:10400625, PubMed:25365219, PubMed:24074955).
  Acts by channeling adaptive and innate immune signaling downstream of CARD domain-containing proteins CARD9, CARD11 and CARD14 to activate NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:24074955).
  Recruited by activated CARD domain-containing proteins: homooligomerized CARD domain-containing proteins form a nucleating helical template that recruits BCL10 via CARD-CARD interaction, thereby promoting polymerization of BCL10, subsequent recruitment of MALT1 and formation of a CBM complex (PubMed:24074955).
  This leads to activation of NF-kappa-B and MAP kinase p38 (MAPK11, MAPK12, MAPK13 and/or MAPK14) pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines (PubMed:18287044, PubMed:27777308, PubMed:24074955).
  Activated by CARD9 downstream of C-type lectin receptors; CARD9-mediated signals are essential for antifungal immunity (PubMed:26488816).
  Activated by CARD11 downstream of T-cell receptor (TCR) and B-cell receptor (BCR) (PubMed:18264101, PubMed:18287044, PubMed:27777308, PubMed:24074955).
  Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK (PubMed:10187815).

Recommended Dilution Buffer

• MRO-0253YJ
• Reconstitution Buffer PBS